# SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus

> **NCT06364930** · PHASE4 · RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 412 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab
- **DRUG:** Placebo 10mg Tab

## Key facts

- **NCT ID:** NCT06364930
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-26
- **Primary completion:** 2030-10-31
- **Final completion:** 2031-03-30
- **Target enrollment:** 412 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06364930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06364930, "SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06364930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*